264 results about "Recombinant antigen" patented technology

The invention relates to an HPV16 type E6 oncoprotein monoclonal antibody as well as a preparation method and application thereof. The monoclonal antibody specifically bound with the HPV16E6 recombinant antigen is obtained through screening, the monoclonal antibody is applied to a biotin-avidin amplification ELISA system, the E6 oncoprotein of HPV16 can be specifically detected, the sensitivity is 100 pg / mL, the monoclonal antibody does not intersect with oncoprotein of other high-risk HPV, and the E6 oncoprotein of HPV16 can be specifically detected. High specificity and sensitivity are shown for cervical exfoliated cell sample detection of normal people, CIN3 people and cervical cancer people, and the method can be applied to early screening of cervical cancer in the future; compared with traditional exfoliative cytology examination, the method is faster and more accurate, meanwhile, the risk of false positive and misdiagnosis caused by too high sensitivity of nucleic acid detection can be avoided, and the method has very high application value.

The invention belongs to the technical field of medical biology, and particularly discloses a mycoplasma hyopneumoniae recombinant antigen, an expression vector, a recombinant bacterium and application. The invention provides a construction method of a mycoplasma hyopneumoniae recombinant antigen, which is characterized in that a mycoplasma hyopneumoniae P97 protein R1 region is modified to construct the mycoplasma hyopneumoniae recombinant antigen as shown in SEQ ID No.1. The mycoplasma hyopneumoniae recombinant antigen is cloned into an expression vector, and a recombinant engineering bacterium is obtained by using a genetic transformation means. The recombinant engineering bacterium can stably express the recombinant antigen of the mycoplasma hyopneumoniae, can be prepared into an oral living bacterium preparation, has the characteristics of safety, effectiveness, rapidness and the like, and particularly can prevent infection of the mycoplasma hyopneumoniae to pigs without an immune response process.

The invention discloses a fusion protein, a fusion protein gene, a recombinant cell, a recombinant antigen, a reagent for detecting an anti-myelin sheath related glycoprotein antibody and a preparation method, a detection method and application of the reagent, the fusion protein is MAG, GlcAT-P and HNK-1ST fusion protein, and the MAG, GlcAT-P and HNK-1ST fusion protein is formed by sequentially connecting MAG, a GGGGS sequence, EGFP, P2A, GlcAT-P, T2A and HNK-1ST; the amino acid sequence of the MAG, GlcAT-P and HNK-1ST fusion protein is as shown in SEQ ID NO. 1; the kit can be used for detecting the MAG autoantibody, has excellent detection sensitivity and specificity, and can ensure the detection accuracy especially for the detection in a low titer range.

The invention provides an HIV recombinant antigen for detecting an HIV antibody, and belongs to the technical field of immunodiagnosis. The invention particularly relates to an HIV (Human Immunodeficiency Virus) recombinant antigen, a nucleic acid molecule, an expression vector, a host cell, a reagent, a kit and application. According to the invention, the recombinant HIV antigen protein is used for a labeled terminal, so that the marker activity of the recombinant HIV antigen can be remarkably improved, the non-specific immune binding activity can be reduced, and the sensitivity is improved.

The invention belongs to the field of biological detection, and particularly relates to a kit for detecting serum autoantibodies and application of the kit. The kit comprises a standard substance, an elisa plate coated with recombinant antigen protein, an elisa secondary antibody, a developing solution and a reaction stop solution, and the recombinant antigen protein is a recombinant HNRNPA3 antigen protein with a His tag. The kit for detecting the breast cancer, provided by the invention, is high in specificity, can specifically detect the content of the HNRNPA3 autoantibody, and is crucial for early screening and diagnosis of cancers as an auxiliary diagnosis means for the breast cancer with high expression of the HNRNPA3 autoantibody.

The invention relates to the related technical field of detection of a porcine respiratory and reproductive disorder virus antibody, and particularly provides a recombinant antigen and an ELISA (enzyme-linked immunosorbent assay) detection kit for detecting the porcine respiratory and reproductive disorder virus antibody based on the recombinant antigen. The invention provides a recombinant antigen. The recombinant antigen is selected from a structure as shown in a formula (I), wherein the AAS1 and the AAS2 independently represent an amino acid sequence as shown in SEQ ID NO.8 or an amino acid sequence as shown in SEQ ID NO.9, and the AAS1 and the AAS2 represent different amino acid sequences; l represents an amino acid sequence # imgabs0 # in the direction from the N terminal to the C terminal, and n is selected from integers from 1 to 5. The recombinant antigen disclosed by the invention can be specifically combined with a porcine respiratory and reproductive disorder virus antibody, so that false positive detection results caused by interfering substances are greatly reduced. (1) AAS1-L-AAS2.

New vaccine compositions comprising a modified antigen bound to the surface of an adjuvant or carrier by electrostatic interactions are disclosed. The antigen of the vaccine composition is presented in a defined orientation on an adjuvant surface such that epitope accessibility is altered and an immune response is redirected toward specific epitopes. In some embodiments the vaccine composition comprises one or more recombinant antigen polypeptides adsorbed to an alum particle. In some embodiments, the recombinant antigen polypeptide comprises a Region of Repetitive Carboxylic Groups (RRC) or a Region of Repetitive Lysyl / Guanidino Groups (RRL).

This application discloses a feline allergen Fel d1 egg yolk antibody and its preparation method and application, comprising: obtaining PCR amplification products through PCR amplification; constructing a recombinant plasmid by ligating the PCR amplification products with pET-28a(+); transforming the recombinant plasmid into Rosetta competent cells to obtain transformants; obtaining recombinant antigens by extracting proteins from the transformants; obtaining a subunit vaccine by mixing and emulsifying the recombinant antigens with white oil adjuvant; administering the subunit vaccine to laying hens to obtain immunized egg yolk liquid; adding Tris-HCl buffer and polyethylene glycol to the egg yolk liquid and centrifuging to collect the protein aqueous phase; filtering the protein aqueous phase to obtain a filtrate, adding polyethylene glycol, mixing, centrifuging to collect the precipitate; mixing the precipitate with PBS buffer, adding ammonium sulfate, and centrifuging to obtain the egg yolk antibody. This invention solves the problem that the safety and economy of existing feline allergy treatment methods cannot be simultaneously achieved.

The invention provides a joint detection test strip for dengue virus and Zika virus antigens and antibodies and a preparation method of the joint detection test strip. According to the combined detection test strip, the combined detection test strip with the dengue virus NS1 antigen and the dengue virus IgG / IgM antibody adopts a multi-site recombinant antigen labeling or multi-site recombinant antibody coating form, so that the sensitivity of a reagent is improved; the problems of poor specificity and release residue of latex microspheres are solved by optimizing the confining liquid; colored latex microspheres are used as a marker, a detection target is more intuitively distinguished according to line colors, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is more quickly improved, and the dengue virus NS1, the Zika virus NS1 antigen, the dengue virus IgG / IgM antibody and the Zika virus IgG / IgM antibody can be detected at the same time; and the kit is convenient to carry, simple to operate, convenient for on-site instant detection and capable of performing large-scale preliminary screening.

The invention discloses a method for establishing duck hepatitis virus antibody ELISA (enzyme-linked immuno sorbent assay) detection, which comprises the following steps: firstly, preparing experimental materials, and then cloning and antigenicity analysis of structural genes, inducible expression of positive recombinants in escherichia coli, expression and purification of recombinant proteins, antigenicity analysis of the recombinant proteins and establishment of a recombinant antigen VP3 indirect ELISA method. Finally, VP0, VP3 and VP1 recombinant proteins can react with duck anti-DHV-1 positive serum and have good antigenicity, indirect ELISA results show that under the same coating concentration, the P / N value of the fusion protein GST-VP3 serving as a coating antigen is higher than that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein GST-VP3 serving as the coating antigen, it is indicated that the antigenicity of the fusion protein GST-VP3 is better than that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein and the result is consistent with the prediction result.

The present disclosure provides a recombinant antigen which is capable of eliciting protective immunity against all three stages of the Plasmodium life cycle, as well as compositions for and methods of preventing or inhibiting primary infection, disease severity, and transmission of malaria.

This invention discloses an ANXA1 recombinant antigen, its preparation method, and its applications, belonging to the field of biodetection technology. The ANXA1 recombinant antigen of this invention is based on the wild-type ANXA1 protein shown in SEQ ID NO.1, obtained by deleting its first epitope-masking region, thus making the epitope more easily exposed. Verification has shown that, compared to the full-length ANXA1 antigen, the ANXA1 recombinant antigen of this invention has improved sensitivity in early lung cancer detection, and its detection performance is significantly superior to commercially available ANXA1 recombinant antigens. Therefore, the ANXA1 recombinant antigen of this invention provides a new approach for the early auxiliary diagnosis of lung cancer.

The application provides a kit for detecting neutralizing antibodies of a novel coronavirus, comprising an immunochromatography test paper, the immunochromatography test paper comprising a backing plate and a sample pad, a conjugate pad, a detection pad and a water absorption pad arranged on the backing plate in sequence; the detection pad is provided with a detection line and a quality control line; the sample pad is coated with a recombinant antigen, the recombinant antigen being a fusion protein SARS-CoV-2S-RBD-Fc formed by fusing SARS-CoV-2S-RBD with the Fc fragment of IgG antibody; the conjugate pad is coated with SARS-CoV-2ACE2 labeled with nanoparticles; and the detection line is coated with a polyantibody of anti-IgG antibody. The kit for detecting the application utilizes the principle of competition and sandwich detection, can quickly and simply realize effective detection of neutralizing antibodies of the novel coronavirus, has low cost, high sensitivity and high specificity, and has a good popularization and application prospect.

The present application relates to the technical field of molecular biology, and particularly relates to a human parainfluenza virus type I HN recombinant antigen and application thereof. The amino acid sequence of the human parainfluenza virus type I recombinant HN recombinant antigen provided by the present application is shown as SEQ ID NO:1. The amino acid sequence provided by the present application can be efficiently expressed in insect cells, and a stable antigen can be obtained after purification and preparation of the expression product, and the antigen has high immunological activity and can be used for serum specific antibody detection or parainfluenza virus infection diagnosis.

The present invention relates to: a vector capable of simultaneously producing an antigen of porcine circovirus 2d, recently prevalent in Korea, an antigen of porcine circovirus 2a, which has caused diseases from the past to the present, a porcine circovirus 2 cellular immunity recombinant protein, and a p65 recombinant protein of Mycoplasma hyopneuminiae, which causes porcine mycoplasma pneumonia; a vaccine against PCV2 and Mycoplasma, the vaccine comprising four types of antigens, Mycoplasma hyopneuminiae dead cells, and Mycoplasma hyorhinis dead cells produced by the vector; a method for producing same; and a use thereof.

The invention discloses a recombinant antigen protein, a recombinant vector, a recombinant host cell, a virus-like particle and application thereof and a vaccine, and relates to the technical field of antigen preparation, the recombinant antigen protein comprises an icosahedral porcine circovirus capsid protein and an A104R protein loaded on the surface of the icosahedral porcine circovirus capsid protein, the A104R protein comprises a protein coded by an African swine fever virus A104R gene. The recombinant antigen protein capable of simultaneously reacting with positive serum of the African swine fever virus and positive serum of the porcine circovirus is prepared, and the vaccine prepared by mixing the recombinant antigen protein with an adjuvant can effectively stimulate a pig body to generate specific antibodies of the African swine fever virus and the porcine circovirus; therefore, reference is provided for joint defense of the two viruses. The recombinant antigen protein provided by the invention has the characteristics of stable expression, high yield and high solubility.

This invention provides a recombinant conjugate protein against EBV virus and its application. The recombinant conjugate protein is a conjugate of recombinant protein HBc-SC and recombinant EBV antigen protein. In the recombinant conjugate protein, the molar ratio of recombinant protein HBc-SC to recombinant EBV antigen protein is 1:1 to 1:12. The amino acid sequence of the recombinant protein HBc-SC is shown in SEQ ID NO:1. The recombinant EBV antigen protein includes a recombinant gHgL fragment and a tag sequence. The recombinant gHgL fragment is shown in SEQ ID NO:3. The tag sequence is shown in SEQ ID NO:5, and the tag sequence is located at the C-terminus of the recombinant EBV antigen protein. The recombinant conjugate protein provided by this invention can induce strong humoral immunity, significantly increasing neutralizing antibody titers in epithelial cells and B cells, making it an excellent candidate vaccine for preventing EBV virus infection.

The invention discloses a porcine reproductive and respiratory syndrome antibody detection colloidal gold test strip and a preparation method thereof, and belongs to the technical field of veterinary biology. According to the present invention, by optimizing the immune peptide sequence and constructing the recombinant antigen protein expression vector, the efficient expression and purification of the target protein P1NP2 are successfully achieved; specific binding of the recombinant antigen protein and the PRRSV antibody is verified by using a Western blot technology, and the reliability and accuracy of the recombinant antigen protein in antibody detection are proved. A simple, convenient, rapid and efficient PRRSV antibody detection colloidal gold test strip detection method is established by utilizing an antigen detection colloidal gold test strip principle, and the performance of the PRRSV antibody detection colloidal gold test strip detection method is fully evaluated and verified. The porcine reproductive and respiratory syndrome antibody detection colloidal gold test strip is successfully developed, a commercialized colloidal gold test strip box is successfully prepared, and the colloidal gold test strip has important significance on the diagnosis and prevention and control of PRRSV (Porcine Reproductive and Respiratory Syndrome Virus).

The invention relates to the technical field of antibody detection, in particular to a recombinant antigen and application of a transfected living cell immunofluorescence method of the recombinant antigen in anti-myelin oligodendroglia glycoprotein IgG antibody detection. The method comprises the following steps: constructing a myelin sheath oligodendroglia glycoprotein expression plasmid, with an expression plasmid vector being pcdna3.1-target gene-linker-* 3Flag-P2A-EGFP, an amino acid sequence of the expression plasmid gene being as shown in SEQ ID NO: 1, a base sequence of the expression plasmid gene being as shown in SEQ ID NO: 2, carrying out cell transfection to make the expression plasmid enter a target cell, culturing for 16-28 h to obtain a cell immobilized with the expression plasmid, and purifying the cell to obtain the myelin sheath oligodendroglia glycoprotein. The kit can be used for detecting the anti-myelin oligodendroglia glycoprotein IgG antibody by an immunofluorescence staining method. The problems of antigen spatial conformation change, epitope shielding or cell shrinkage of cells are solved, and the detection sensitivity is improved.

The application provides a recombinant antigen protein p22 of an African swine fever virus, a monoclonal antibody and application. The application provides a recombinant antigen protein of an African swine fever virus. The application provides an antibody or antigen binding fragment thereof of the recombinant antigen protein of the African swine fever virus. The application also provides a hybridoma cell. The application also provides a rapid detection test paper card of the African swine fever antibody. The recombinant antigen protein of the African swine fever virus provided by the application has higher affinity to the African swine fever antibody, higher specificity and better stability, and can be used for rapid and accurate detection of the African swine fever virus.

The invention discloses a preparation method and application of a vibrio outer membrane protein A multi-epitope antigen and a recombinant antigen thereof, and is characterized in that a protein multi-epitope antigen sequence synthesized by outer membrane proteins of vibrio splendidus, vibrio parahaemolyticus and vibrio alginolyticus is designed by utilizing a multi-epitope technology, and the amino acid sequence of the protein multi-epitope antigen sequence is shown as SEQ ID NO.4; the preparation method of the multi-epitope recombinant antigen comprises the following steps: synthesizing a multi-epitope gene according to a multi-epitope antigen amino acid sequence, connecting the multi-epitope gene to a pET-28a (+) vector, transforming a plasmid containing the multi-epitope gene into a protein expression type competent cell, screening out positive clones, and performing protein expression; the method comprises the following steps: carrying out protein purification by using affinity chromatography to obtain a multi-epitope recombinant antigen, further preparing a multi-epitope antibody by using the multi-epitope recombinant antigen, and detecting whether a to-be-detected sample solution contains vibrio or not by using the multi-epitope antibody as a labeled protein and using a trace thermophoresis technology, so that the method has the advantages of high detection speed and strong specificity.

The invention discloses a MAGE A1 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the MAGE A1 recombinant antigen disclosed by the invention is as shown in SEQ ID NO. 1. Through verification, compared with a full-length MAGE A1 antigen, the MAGE A1 recombinant antigen disclosed by the invention has the advantage that the sensitivity of the MAGE A1 recombinant antigen in early lung cancer detection is improved. Therefore, the MAGE A1 recombinant antigen provides a new way for early auxiliary diagnosis of lung cancer.

The present invention discloses a recombinant antigen protein SecG of Helicobacter pylori and its preparation method and application. The amino acid sequence of the recombinant antigen protein SecG is shown in SEQ ID NO: 1, and the nucleotide sequence of the recombinant antigen protein SecG encoding gene is shown in SEQ ID NO: 2. The present invention obtains a high-purity antigen protein through the steps of plasmid construction, induced expression, affinity chromatography and exchange chromatography purification. The purification process is simple, low in cost, and highly operable. The antigen prepared after purification has high immunogenicity and immune titer and can be used as a genetically engineered subunit vaccine. As an important component protein in the membrane transport protein of Helicobacter pylori, the antigen protein SceG will become one of the most promising candidate antigens in the development of Helicobacter pylori genetically engineered vaccines.

The present invention relates to a lymphocyte comprising a recombinant nucleic acid encoding a fusion protein comprising interleukin-15 (IL-15) fused to interleukin-21 (IL-21), and optionally further comprising a recombinant antigen receptor and further optionally rendered independent of CD28 co-stimulation and resistant to exhaustion as caused by checkpoint protein expression and activation. The invention further encompasses the use of such lymphocytes, particularly in therapeutic applications such as adoptive cell therapy for cancer, autoimmune diseases, or infectious diseases. Also included within the scope of the invention are fusion proteins comprising IL-15 and IL-21 domains, nucleic acids encoding such fusion proteins, and cells—such as lymphocytes or other suitable host cells—comprising these nucleic acids.

The present application relates to the technical field of antibodies, in particular to preparation and application of anti-influenza B virus monoclonal antibody, and provides the antibody and application thereof, nucleic acid molecule, expression vector, genetic engineering biological material, quality control product and preparation method, reagent and kit thereof.The anti-FluB monoclonal antibody can be used as quality control product and calibration product, can significantly cause enzyme-linked immuno reaction with Victoria and Yamagata system recombinant antigens of FluB virus HA gene, and the 37 DEG C acceleration stability experiment result shows that it meets the kit use requirement, the preparation method is simple, and is suitable for mass production.

This invention relates to an ELISA detection kit for porcine reproductive and respiratory syndrome virus (PRRSV) based on M-GP5 recombinant protein, and belongs to the field of ELISA detection technology. The kit includes recombinant (M-GP5) antigen protein, an ELISA plate, blocking buffer, primary antibody dilution buffer, enzyme-labeled secondary antibody, secondary antibody dilution buffer, chromogenic solution, stop solution, negative serum, and positive serum. It features high sensitivity, high specificity, and good stability, and can accurately detect PRSV antibodies.

The invention discloses a hybridoma cell strain secreting a CFP10 antibody, the antibody and application of the hybridoma cell strain in magnetic particle chemiluminescence detection, the hybridoma cell strain is 2E7 and is preserved in the China Center for Type Culture Collection on May 14, 2025, and the preservation number is CCTCC NO: C2025162. The monoclonal antibody 2E7 provided by the invention has the advantages of high titer, good specificity and strong affinity with natural antigens and recombinant antigens, and can specifically recognize recombinant antigens rHis-CFP10 and rGST-CFP10 and a CFP10 antigen in a natural antigen H37Ra strain. The magnetic particle chemiluminescence detection method established by the invention is simple to operate, low in cost and wider in applicability.

The application discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence of a non-structural protein NS7 of FCV and a coding sequence of a SpyTag peptide segment through a coding sequence of a linker, then cloning into a baculovirus transfer vector to obtain a recombinant plasmid, and finally integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. The application selects NS7 as a core immunogen, guides the immune system to produce a high cellular immune response, and thus makes up for the deficiency of an existing vaccine in clearing intracellular viruses; meanwhile, a specific T cell epitope is selected in the sequence of NS7 as an immunogen, which can avoid the immunological escape caused by the variation degree of antigens among different strains and virus antigen drift, and thus provides broader protection.

The invention discloses a neutralizing antibody with an AQP3 channel blocking function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The neutralizing antibody can be specifically combined with an extracellular domain of AQP3, after combination, a water channel and a small molecule transport function of the AQP3 are blocked through steric hindrance and conformation change, and meanwhile, antigen combination specificity is reserved. The preparation method is realized through'recombinant antigen-immunization-B cell screening culture-recombinant antibody expression and affinity purification-ELISA detection ', and the functions of the antibody are ensured. The antibody can be efficiently combined with AQP3 positive cells, is strong in targeting property and high in specificity (the serum titer reaches 1: 1024 * 10, and the purified antibody titer is greater than or equal to 1: 128 * 10), and can be independently used or combined with a nano-carrier for treating related diseases, so that the technical bottleneck that a common AQP3 antibody can only be combined and cannot efficiently play a blocking role is solved.

The application provides a combined detection test strip for dengue virus, Zika virus antigen and antibody and a preparation method thereof; the combined detection test strip of the application adopts a multi-site recombinant antigen marking or multi-site recombinant antibody coating form for the combined detection test strip for dengue virus NS1 antigen and dengue virus IgG / IgM antibody, thereby improving the sensitivity of the reagent; the application also overcomes the problems of poor specificity and release residue of the latex microspheres by optimizing a blocking solution; color latex microspheres are used as the markers, the target is more intuitively detected according to the color of the lines, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is improved, dengue virus NS1, Zika virus NS1 antigen, dengue virus IgG / IgM antibody detection and Zika virus IgG / IgM antibody can be simultaneously detected; moreover, the application is convenient to carry and easy to operate, is convenient for on-site instant detection and can be used for large-scale preliminary screening.